{"id":"W4410812834","doi":"10.1200/jco.2025.43.16_suppl.11121","title":"Final patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations receiving initial treatment with talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in the TALAPRO-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Homologous recombination; Oncology; Internal medicine; PARP inhibitor; Gene; Cancer; Poly ADP ribose polymerase; Androgen receptor; Genetics; Pathology; Biology; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002849114,0.0006526772,0.0007217726,0.0006418411,0.0002727575,0.0006279231,0.0004790617,0.0004171332,0.001797252],"category_scores_gemma":[0.002493656,0.0002429496,0.002020877,0.0007988121,0.0002490366,0.0006454351,0.0007480418,0.0009728943,0.0002736314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003598865,"about_ca_system_score_gemma":0.0003022723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00171574,"about_ca_topic_score_gemma":0.002949832,"domain_scores_codex":[0.9990684,0.000444447,0.00008475861,0.0001434625,0.0001501648,0.0001086383],"domain_scores_gemma":[0.9977151,0.0004592144,0.001171557,0.0001152975,0.0002104245,0.0003284141],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1055176,0.001456453,0.8204659,0.001174911,0.008858592,0.0001437468,0.0002976606,0.004005802,0.001176348,0.0001636887,0.004589251,0.05215013],"study_design_scores_gemma":[0.002686944,0.01532733,0.9756437,0.00006488151,0.002395421,0.0002071076,0.0001101085,0.00120321,0.0004511545,0.000106273,0.001765467,0.00003832806],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856147,0.002978842,0.0003840945,0.0001231308,0.00003864046,0.0001822527,0.009129412,0.00002997387,0.001518989],"genre_scores_gemma":[0.9905754,0.000468347,0.0003078547,0.00007858907,0.00003622059,0.0001838707,0.007738342,0.000005319333,0.0006058867],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002849114,"threshold_uncertainty_score":0.01506776,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1057754304687696,"score_gpt":0.4559922376212079,"score_spread":0.3502168071524383,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}